3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
69
Neoplasms
28
Neoplasm Metastasis
14
Colorectal Neoplasms
9
Multiple Myeloma
6
Thyroid Neoplasms
5
Skin Neoplasms
5
Lymphoma, Non-Hodgkin
5
Carcinoma, Non-Small-Cell Lung
5
Thyroid Cancer, Papillary
4
Leukemia, Hairy Cell
4
Hematologic Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Breast Neoplasms
3
Wilms Tumor
2
Thyroid Carcinoma, Anaplastic
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoma
2
Interventions
binimetinib
2
Sodium Chloride
2
Aminolevulinic Acid
2
palbociclib
1
methyl 5-aminolevulinate
1
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Trabectedin
1
Spironolactone
1
Radiotherapy
1
Radiation
1
Photochemotherapy
1
Paclitaxel
1
Low-Level Light Therapy
1
Leuprolide
1
Injections, Intradermal
1
Gonadotropin-Releasing Hormone
1
Fluorouracil
1
Floderm topical cream
1
Everolimus
1
Equipment and Supplies
1
Docetaxel
1
Dacarbazine
1
Cetuximab
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Skin Diseases
×
Vemurafenib
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA